RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis

Anti-Cancer Drugs

Volumn 23, Issue 8, 2012, Pages 788-802

  Pu, Chun Yan ^a   Xu, Han Mei ^a   Hu, Jia Liang ^a   Zheng, Heng ^a   Huang, Xiao Feng ^b   Zhang, Chi ^a   Yang, Yong Jing ^a   Li, Yong Bing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

antiangiogenesis; antitumor; endostatin; integrin; RGD position

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EDSM; EDSM X; EDSM Y; ENDOSTATIN; PACLITAXEL; POLYPEPTIDE; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RAT; RECEPTOR BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, THORACIC; CELL ADHESION; CELL MOVEMENT; DRUG DELIVERY SYSTEMS; ENDOSTATINS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RATS, SPRAGUE-DAWLEY;

EID: 84864399732     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283530447     Document Type: Article

References (36)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. (Pubitemid 38702844)
3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
4. Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338. (Pubitemid 44528723)
5. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24. (Pubitemid 46630489)
6. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293-4300. (Pubitemid 46630787)
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285. (Pubitemid 28015876)
8. Xu HM, Zhang GY, Ji XD, Cao L, Shu L, Hua ZC. Expression of soluble, biologically active recombinant human endostatin in Escherichia coli. Protein Expr Purif 2005; 41:252-258. (Pubitemid 40607770)
9. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999; 258:345-352. (Pubitemid 29287054)
10. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312:594-607. (Pubitemid 43290336)
11. Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial pequences of endostatin. Clin Cancer Res 2003; 9:5358-5369. (Pubitemid 37413591)
12. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 2003; 283:230-236. (Pubitemid 36269028)
13. Hohenester E, Sasaki T, Olsen BR, Timp R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998; 17:1656-1664. (Pubitemid 28119119)
14. Chen R, Weng ZP. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 2002; 47:281-294. (Pubitemid 34438678)
15. Pierce B, Weng ZP. ZRANK: reranking protein docking predictions with an optimized energy function. Proteins 2007; 67:1078-1086. (Pubitemid 46753952)
16. Xiong JP, Stehle T, Zhang RG, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin avb3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296:151-155. (Pubitemid 34280076)
17. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin a5b1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62:5580-5589.
18. Sudhakar A, Sugimoto H, Yang CQ, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by avb3 and a5b1 integrins. Proc Natl Acad Sci USA 2003; 100:4766-4771. (Pubitemid 36457804)
19. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo CR, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98:1024-1029. (Pubitemid 32121180)
20. Sun RH, Zheng H, Fang ZZ, Yao WB. Rational design of aminoacyl-tRNA synthetase specific for p-acetyl-L-phenylalanine. Biochem Biophys Res Commun 2010; 391:709-715.
21. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787-787.
22. Arap W, Pasqualini R, Rouslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380. (Pubitemid 28063372)
23. Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 2005; 11: 6317-6324. (Pubitemid 41262963)
24. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005; 102:191-201. (Pubitemid 40093785)
25. Wang H, Yan Z, Shi JH, Han W, Zhang YQ. Expression, purification, and characterization of a neovasculature targeted rmhTNF-a in Escherichia coli. Protein Expr Purif 2006; 45:60-65. (Pubitemid 41773310)
26. Xu HM, Yin RT, Chen LS, Siraj S, Huang XF, Wang M, et al. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjug Chem 2008; 19:1980-1986.
27. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40:2373-2378. (Pubitemid 32171709)
28. Yin RT, Zheng H, Xi T, Xu HM. The effect of RGD-4C position is more important than disulfide bonds on anti-angiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide. Bioconjug Chem 2009; 21:1142-1147.
29. Xu HM, Pan L, Ren YL, Yang YJ, Huang XF, Liu ZD. An RGD-modified angiogenesis inhibitor HM-3 dose: dual function during cancer treatment. Bioconjug Chem 2011; 22:1386-1393.
30. Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 2001; 11:48-53. (Pubitemid 32119277)
31. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9:804-820.
32. Kim S, Bakre M, Yin H, Varner JA. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002; 110:933-941.
33. Kim S, Harris M, Varner JA. Regulation of integrin avb3-mediated endothelial cell migration and angiogenesis by integrin a5b1 and protein kinase A. J Biol Chem 2000; 275:33920-33928.
34. Gramoun A, Shorey S, Bashutski JD, Dixon SJ, Sims SM, Heersche JN, et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem 2007; 102:341-352. (Pubitemid 47519408)
35. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17:1225-1235.
36. Wickström SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004; 279:20178-20185. (Pubitemid 38623462)